Fellowship · Chapel Hill, NC
Sponsored by University of North Carolina Hospitals
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 418 citations · Robert Ferris
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
The Lancet. Oncology · 2021 · 557 citations · Robert Ferris
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment.
Nature reviews. Cancer · 2023 · 278 citations · Robert Ferris
Systemic Therapy for Melanoma: ASCO Guideline Update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 188 citations · Michael Meyers
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies.
Cancer cell · 2025 · 69 citations · Robert Ferris
B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma.
Nature communications · 2021 · 317 citations ·
Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer.
Nature · 2021 · 291 citations · Mihir Patel
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 143 citations · Robert Ferris